RT Journal Article
SR Electronic
T1 Age-seroprevalence curves for the multi-strain structure of influenza A virus
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.03.21249160
DO 10.1101/2021.01.03.21249160
A1 Dao Nguyen Vinh
A1 Nguyen Thi Duy Nhat
A1 Erwin de Bruin
A1 Nguyen Ha Thao Vy
A1 Tran Thi Nhu Thao
A1 Huynh Thi Phuong
A1 Pham Hong Anh
A1 Stacy Todd
A1 Tran Minh Quan
A1 Nguyen Thi Le Thanh
A1 Nguyen Thi Nam Lien
A1 Nguyen Thi Hong Ha
A1 Tran Thi Kim Hong
A1 Pham Quang Thai
A1 Marc Choisy
A1 Tran Dang Nguyen
A1 Cameron P Simmons
A1 Guy E Thwaites
A1 Hannah E Clapham
A1 Nguyen Van Vinh Chau
A1 Marion Koopmans
A1 Maciej F Boni
YR 2021
UL http://medrxiv.org/content/early/2021/01/04/2021.01.03.21249160.abstract
AB The relationship between age and seroprevalence provides the simplest and least expensive approach to computing the annual attack rate of an infectious disease. However, many pathogens circulate as multiple serologically distinct strains, with no single assay able to determine seropositivity or seronegativity to an entire clade or family of co-circulating pathogens. An approach is needed to describe population exposure to an antigenically variable group of pathogens without focusing on any particular strain or serotype in the group. In this study, we focus on the two-subtype multi-strain taxonomy of human influenza A virus. We describe a data set of 24,402 general-population serum samples collected in central and southern Vietnam between 2009 to 2015, and assayed for influenza HA1 antibodies to eleven different strains of human influenza A (both H3 and H1 subtypes). We find that a principal components decomposition of the data results in the first principal component PC1 being an appropriate surrogate for seroprevalence (or composite antibody titer) which can be further decomposed for H1 and H3 contribution to the serological profile. Using this approach, we are able to provide the first ELISA-based standardized measurements of serology to reconstruct population exposure history, which correlates well with known influenza epidemiology. Annual attack rates in Vietnam are estimated at 25.6% (95% CI: 24.1% – 27.1%) for H3 and 16.0% (95% CI: 14.7% – 17.3%) for H1, with some variation in location-specific attack rates. The remaining principal components act as descriptors of influenza history and sort the population by birth year. The novel contributions of this analysis are (1) the introduction of dimensionality reduction on human antibody profiles to construct an age-seroprevalence relationship for an antigenically variable pathogen, (2) an analysis of >24,000 individuals, using >260,000 serological data points in total, allowing us to construct age-seroprevalence relationships with the precision of modern big data studies, and (3) a description of long-term attack rates in a non-vaccinated setting showing the natural history of influenza A virus in a densely-populated tropical country.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the Wellcome Trust Grant 089276/B/09/7 (DNV, NTDT, PHA, GET), a Wellcome Trust Sir Henry Dale Fellowship and Enhancement Award (MFB, NHTV, TTNT, HTP, PHA, NTLT, HEC), Wellcome Trust Grant 097465/B/11/Z (ST), by a British Medical Association HC Roscoe Award (2011-2014). CPS is funded by the National Health and Medical Research Council of Australia. MK and EdB are funded by Dutch Ministry of Economic Affairs, Agriculture, and Innovation, Castellum Project.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Scientific and Ethical Committee of the Hospital for Tropical Diseases in Ho Chi Minh City and the Oxford Tropical Research Ethics Committee at the University of Oxford.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData and code are posted publicly at https://github.com/bonilab/seroepi-02FL-influenza-vietnam-PCA https://github.com/bonilab/seroepi-02FL-influenza-vietnam-PCA